Virbac : Declaration of the number of shares and voting rights 10/2024 DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital(Article 223-16 of the General regulations of the French Financial Market Authority – Autoritédes Marchés Financiers) Quotation place: Euronext ParisCompartiment AISIN code: FR0000031577 DateTotal number of shares representing the share capitalTotal number of voting rightsOctober, 31 20248 390 660Gross total of voting rights : 12 707 824Net total* of voting rights : 12 691 7...
The recovery in growth in the IT & engineering services sector is undermined by the still mixed macroeconomic climate and the setbacks in the automotive and aerospace sectors. The improvement in sector momentum will therefore be minimal in H2 2024 with a growing decorrelation between the US which should be robust and a stagnating Europe. This leads us to adopt a more cautious approach on companies in our sector (revision to our 2025 growth estimates for 12 companies) and to prefer Acc...
La reprise de la croissance du secteur IT & Engineering Services est mise à mal par un contexte macro toujours mitigé et par les déboires des secteurs Auto et Aéro. Ainsi, l’amélioration de la dynamique du secteur sera minimale au S2 2024 et probablement aussi au S1 2025, avec une décorrélation grandissante entre les US qui devraient être solides et une Europe stagnante. Ceci nous amène à adopter une approche plus prudente pour les sociétés de notre secteur (révision de croissance 202...
>T3 : +7,7% et +3,4% à ptcc. (vs +15,2% et +11,3% à ptcc. au S1) - Le CA T3 de Virbac atteint 339 M€, ie. +7,7% (+3,4% à ptcc. vs +5%e attendu par nous). Globion et Sasaeah contribuent à hauteur de 6,5 pt. A 9 mois, le CA se monte à 1 042,1 M€ (+12,6%) avec un CA Animaux de compagnie à +11,9% et un CA Animaux d’élevage à +3,2%. Virbac confirme sa guidance ie. une croissance du CA comprise entre 7% et 9%, +5,5% d’effet périmètre (soit à périmètre réel, entre ...
>Q3: +7.7% and +3.4% l-f-l (vs +15.2% and +11.3% l-f-l in H1) - Virbac’s Q3 sales totalled € 339m, i.e. +7.7% (+3.4% l-f-l vs our forecast of +5%e). Globion and Sasaeah contributed 6.5 points. At 9M, sales stand at € 1,042.1m (+12.6%) with pet sales at +11.9% and livestock sales at +3.2%. Virbac confirmed its guidance of sales growth of 7-9%, a +5.5% scope effect (at real scope, between +12.5% and +14.5%) and an EBIT ratio around 16% of sales.A ...
Virbac: Strong revenue growth as of the end of September at +12.6% and +8.6% at constant exchange rates and scope. 2024 targets maintained. KEY FIGURES Revenue at the end of September €1 042.1M Growth at constant exchange rates and scope1 +8.6% includingcompanion animals +11.9% farm animals +3.2% Growth at constant exchange rates2 +14.0% Overall change +12.6% 1growth at constant exchange rates and scope corresponds to organic growth of sales, excluding exchange rate variations, by calculating the indicato...
VIRBAC: Croissance soutenue du chiffre d’affaires à fin septembre de +12,6% et +8,6% à taux de change et périmètre constants. Maintien des objectifs pour 2024. CHIFFRES CLÉS Chiffre d’affaires à finseptembre 2024 1 042,1 M€ Croissance à taux de change et périmètre constants1 +8,6% dontanimaux de compagnie +11,9% animaux d’élevage +3,2% Croissance à taux de change constants2 +14,0% Évolution globale +12,6% 1l’évolution à taux de change et périmètre constants correspond à la croissance organique des ventes hors variation des taux de change en calculant l...
>+6.4%e forecast after +7.2% in H1 - All told, for Q3 2024 our France healthcare midcap universe should post growth with a slight decline vs H1, i.e. around +6.4%e (this figure should stand at around +5/5.5% excluding the forex effect). Such a trajectory corresponds to a slight slowdown compared to H1 (+7.2% in reported data) and remains slightly higher on an annualised basis (+5.7%e).As a reminder, over 7 years, our sector has performed well and somewhat evenly ...
We measured the impact of the contribution from Michel Barnier’s exceptional tax on 88 stocks exposed to France. Some 17 of them would experience a (negative) impact on their EPS of more than 4% on average over 2024 and 2025: LDC (-8.3%), Synergie (-8%), Eiffage (-7.9%), ADP (-7.9%), Dassault Aviation (-7%), Crit (-6.9%), Derichebourg (-6.3%), Hermès (-5.6%), Safran (-5.6%), Bouygues (-5.6%), M6 (-5.2%), Thales (-5%), TF1 (-4.9%), Nexans (-4.9%), Vinci (-4.7%), Compagnie des Alpes (...
>+6,4%e attendu après +7,2% au S1 - Dans son ensemble notre univers de Midcap Santé France devrait afficher, au T3 2024, une croissance en léger fléchissement par rapport au S1, soit environ +6,4%e (ce chiffre reviendrait à environ +5/5,5%e hors effet devises). Une telle trajectoire correspond à une légère décélération comparée au 1er semestre (+7,2% en données publiées) et reste un peu supérieure au rythme annualisé (+5,7%e).Pour rappel, sur 7 ans, notre secteur...
We measured the impact of the contribution from Michel Barnier’s exceptional tax on 88 stocks exposed to France. Some 17 of them would experience a (negative) impact on their EPS of more than 4% on average over 2024 and 2025: LDC (-8.3%), Synergie (-8%), Eiffage (-7.9%), ADP (-7.9%), Dassault Aviation (-7%), Crit (-6.9%), Derichebourg (-6.3%), Hermès (-5.6%), Safran (-5.6%), Bouygues (-5.6%), M6 (-5.2%), Thales (-5%), TF1 (-4.9%), Nexans (-4.9%), Vinci (-4.7%), Compagnie des Alpes (...
Nous avons mesuré l’impact de la contribution exceptionnelle Barnier sur 88 valeurs exposées à la France. 17 d’entre elles auraient un impact (négatif) sur leurs BPA de plus de 4% en moyenne sur 2024 et 2025 : LDC (-8,3%), Synergie (-8%), Eiffage (-7,9%) ADP (-7,9%), Dassault Aviation (-7%), Crit (-6,9%), Derichebourg (-6,3%), Hermès (-5,6%), Safran (-5,6%), Bouygues (-5,6%), M6 (-5,2%), Thalès (-5%), TF1 (-4,9%), Nexans (-4,9%), Vinci (-4,7%), Compagnie des Alpes (-4,4%), FDJ (-4%). - ...
Nous avons mesuré l’impact de la contribution exceptionnelle Barnier sur 88 valeurs exposées à la France. 17 d’entre elles auraient un impact (négatif) sur leurs BPA de plus de 4% en moyenne sur 2024 et 2025 : LDC (-8,3%), Synergie (-8%), Eiffage (-7,9%) ADP (-7,9%), Dassault Aviation (-7%), Crit (-6,9%), Derichebourg (-6,3%), Hermès (-5,6%), Safran (-5,6%), Bouygues (-5,6%), M6 (-5,2%), Thalès (-5%), TF1 (-4,9%), Nexans (-4,9%), Vinci (-4,7%), Compagnie des Alpes (-4,4%), FDJ (-4%). - ...
Virbac : Declaration of the number of shares and voting rights 09/2024 DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital(Article 223-16 of the General regulations of the French Financial Market Authority – Autoritédes Marchés Financiers) Quotation place: Euronext ParisCompartiment AISIN code: FR0000031577 DateTotal number of shares representing the share capitalTotal number of voting rightsSeptember, 30 20248 390 660Gross total of voting rights : 12 708 271Net total* of voting rights : 12 692...
>Confidence and visibility signalled by management - During its webcast, management underscored market share gains and its regular outperformance of the veterinary market. Our key takeaways are:1/ 2024 guidance is maintained (operating margin 2024E:16%) despite H1 results that topped consensus expectations: it seems cautious in our view, as we indicated yesterday morning (see our First Take), but the CFO highlighted weaker growth in H2 and historic seasonality (w...
>Sérénité et visibilité affichée par le management - Lors de son webcast, le management a souligné les gains de parts de marché et sa surperformance régulière du marché vétérinaire. Nous retenons surtout :1/ La guidance 2024 est maintenue (MOP 24e :16%) malgré un S1 meilleure qu’attendu par le consensus : elle nous semble prudente comme indiqué hier matin (relire notre commentaire), mais le CFO a fait valoir une croissance moindre au S2 et la saisonnalité histori...
Virbac: erratum short Press release Capital reduction_September 13, 2024 This press release rectifies the version of the press release issued by Virbac on September 13, 2024 at 5:45 pm in order to correct a typing error in the amount of Virbac's new share capital. The share capital of Virbac amounts now to €10,488,325 and not €10,448,325 as announced. Focusing on animal health, from the beginningAt Virbac, we provide innovative solutions to veterinarians, farmers and animal owners in more than 100 countries around the world. Covering more than 50 species, our range of products ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.